Potential drug targets for calcific aortic valve disease

Nature Reviews Cardiology

Volumn 11, Issue 4, 2014, Pages 218-231

  Hutcheson, Joshua D ^a   Aikawa, Elena ^a   Merryman, W David ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BONE MORPHOGENETIC PROTEIN 2; CADHERIN; CADHERIN 11; CALCIUM PHOSPHATE; CATHEPSIN S; ELASTIN; G PROTEIN COUPLED RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORFENFLURAMINE; NOTCH1 RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; SEROTONIN 2B RECEPTOR; SEROTONIN RECEPTOR; SIMVASTATIN; UNCLASSIFIED DRUG;

AORTA VALVE DISEASE; AORTA VALVE STENOSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CALCIFIC AORTIC VALVE DISEASE; CALCINOSIS; CARDIOVASCULAR INFLAMMATION; DRUG TARGETING; EXTRACELLULAR MATRIX; FOLLOW UP; HEART LEFT VENTRICLE; HEART VALVE REPLACEMENT; IN VITRO STUDY; INTRACELLULAR SIGNALING; LIPID STORAGE; MEDICATION THERAPY MANAGEMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC CIRCULATION; T LYMPHOCYTE; TREATMENT OUTCOME;

AORTIC VALVE; CALCINOSIS; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HUMANS; PROGNOSIS;

EID: 84897102793     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.1     Document Type: Review

References (166)

1. Go, A S. et al. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 127, e6-e245 (2013
2. Nkomo, V T. et al. Burden of valvular heart diseases: A population-based study. Lancet 368, 1005-1011 (2006
3. Rajamannan, N. M. et al. Calcific aortic valve disease: Not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation 124, 1783-1791 (2011
4. Bach, D. S. Prevalence and characteristics of unoperated patients with severe aortic stenosis. J. Heart Valve Dis. 20, 284-291 (2011
5. Lindman, B. R., Bonow, R. O. & Otto, C. M. Current management of calcific aortic stenosis. Circ. Res. 113, 223-237 (2013
6. Daneault, B. et al. Stroke associated with surgical and transcatheter treatment of aortic stenosis: A comprehensive review. J. Am. Coll. Cardiol. 58, 2143-2150 (2011
7. Sacks, M. S. & Yoganathan, A. P. Heart valve function: A biomechanical perspective. Philos. Trans. R. Soc. Lond. B Biol. Sci. 362, 1369-1391 (2007
8. Sacks, M. S., Smith, D. B. & Hiester, E. D. The aortic valve microstructure: Effects of transvalvular pressure. J. Biomed. Mat. Res. 41, 131-141 (1998
9. Stella, J. A., Liao, J. & Sacks, M. S. Time-dependent biaxial mechanical behavior of the aortic heart valve leaflet. J. Biomech. 40, 3169-3177 (2007
10. Schoen, F. J. Aortic valve structure-function correlations: Role of elastic fibers no longer a stretch of the imagination. J. Heart Valve Dis. 6, 1-6 (1997
11. Stephens, E H., Chu, C. K. & Grande-Allen, K. J. Valve proteoglycan content and glycosaminoglycan fine structure are unique to microstructure, mechanical load and age: Relevance to an age-specific tissue-engineered heart valve. Acta Biomater. 4, 1148-1160 (2008
12. Otto, C M., Kuusisto, J., Reichenbach, D. D., Gown, A. M. & O'Brien, K. D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis: Histological and immunohistochemical studies. Circulation 90, 844-853 (1994
13. Butcher, J. T. et al. Transcriptional profiles of valvular and vascular endothelial cells reveal phenotypic differences: Influence of shear stress. Arterioscler. Thromb. Vasc. Biol. 26, 69-77 (2006
14. Cucina, A. et al. Shear stress induces changes in the morphology and cytoskeleton organisation of arterial endothelial cells. Eur. J. Vasc. Endovasc. Surg. 9, 86-92 (1995
15. Stamatas, G. N. & McIntire, L. V. Rapid flow-induced responses in endothelial cells. Biotechnol. Prog. 17, 383-402 (2001
16. Butcher, J. T. & Nerem, R. M. Valvular endothelial cells and the mechanoregulation of valvular pathology. Philos. Trans. R. Soc. Lond. B Biol. Sci. 362, 1445-1457 (2007
17. Sucosky, P., Balachandran, K., Elhammali, A., Jo, H. & Yoganathan, A. P. Altered shear stress stimulates upregulation of endothelial VCAM 1 and ICAM 1 in a BMP 4 and TGF β1 dependent pathway. Arterioscler. Thromb. Vasc. Biol. 29, 254-260 (2009
18. Balachandran, K. et al. Cyclic strain induces dual-mode endothelial-mesenchymal transformation of the cardiac valve. Proc. Natl Acad. Sci. USA 108, 19943-19948 (2011
19. Bischoff, J. & Aikawa, E. Progenitor cells confer plasticity to cardiac valve endothelium. J. Cardiovasc. Transl. Res. 4, 710-719 (2011
20. Holliday, C. J., Ankeny, R. F., Jo, H. & Nerem, R. M. Discovery of shear-And side-specific mRNAs and miRNAs in human aortic valvular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 301, H856-H867 (2011
21. Simmons, C. A., Grant, G. R., Manduchi, E. & Davies, P. F. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ. Res. 96, 792-799 (2005
22. Gould, S. T., Srigunapalan, S., Simmons, C. A. & Anseth, K. S. Hemodynamic and cellular response feedback in calcific aortic valve disease. Circ. Res. 113, 186-197 (2013
23. Ankeny, R F. et al. Preferential activation of SMAD1/5/8 on the fibrosa endothelium in calcified human aortic valves-Association with low BMP antagonists and SMAD6. PLoS ONE 6, e20969 (2011
24. Hergenreider, E. et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat. Cell Biol. 14, 249-256 (2012
25. Butcher, J T. & Nerem, R. M. Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: Effects of steady shear stress. Tissue Eng. 12, 905-915 (2006
26. Tseng, H et al. A three-dimensional co-culture model of the aortic valve using magnetic levitation. Acta Biomater. 10, 173-182 (2014
27. Bosse, K. et al. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. J. Mol. Cell. Cardiol. 60, 27-35 (2013
28. Rabkin-Aikawa, E., Farber, M., Aikawa, M. & Schoen, F. J. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J. Heart Valve Dis. 13, 841-847 (2004
29. Filip, D. A., Radu, A. & Simionescu, M. Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ. Res. 59, 310-320 (1986
30. Chester, A. H. & Taylor, P. M. Molecular and functional characteristics of heart-valve interstitial cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 362, 1437-1443 (2007
31. Hinz, B. et al. The myofibroblast: One function, multiple origins. Am. J. Pathol. 170, 1807-1816 (2007
32. Mohler, E R. 3rd et al. Bone formation and inflammation in cardiac valves. Circulation 103, 1522-1528 (2001
33. Chen, J. H., Yip, C. Y., Sone, E. D. & Simmons, C. A. Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am. J. Pathol. 174, 1109-1119 (2009
34. New, S. E. & Aikawa, E. Cardiovascular calcification: An inflammatory disease. Circ. J. 75, 1305-1313 (2011
35. Demer, L L& Tintut, Y. Vascular calcification: Pathobiology of a multifaceted disease. Circulation 117, 2938-2948 (2008
36. Freeman, R. V. & Otto, C. M. Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation 111, 3316-3326 (2005
37. Ortlepp, J R., Schmitz, F., Bozoglu, T., Hanrath, P. & Hoffmann, R. Cardiovascular risk factors in patients with aortic stenosis predict prevalence of coronary artery disease but not of aortic stenosis: An angiographic pair matched case-control study. Heart 89, 1019-1022 (2003
38. Weiss, R. M., Miller, J. D. & Heistad, D. D. Fibrocalcific aortic valve disease: Opportunity to understand disease mechanisms using mouse models. Circ. Res. 113, 209-222 (2013
39. Miller, J. D., Weiss, R. M. & Heistad, D. D. Calcific aortic valve stenosis: Methods, models, and mechanisms. Circ. Res. 108, 1392-1412 (2011
40. Adiguzel, E., Ahmad, P. J., Franco, C. & Bendeck, M. P. Collagens in the progression and complications of atherosclerosis. Vasc. Med. 14, 73-89 (2009
41. Libby, P. The interface of atherosclerosis and thrombosis: Basic mechanisms. Vasc. Med. 3, 225-229 (1998
42. Newby, A. C. & Zaltsman, A. B. Fibrous cap formation or destruction-The critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc. Res. 41, 345-360 (1999
43. Libby, P. Collagenases and cracks in the plaque. J. Clin. Invest. 123, 3201-3203 (2013
44. Libby, P. & Sasiela, W. Plaque stabilization: Can we turn theory into evidence?. Am. J. Cardiol. 98, 26P-33P (2006
45. Lin, T. C. et al. Mechanical response of a calcified plaque model to fluid shear force. Ann. Biomed. Eng. 34, 1535-1541 (2006
46. Saremi, A., Bahn, G. & Reaven, P. D. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 35, 2390-2392 (2012
47. Houslay, E S. et al. Progressive coronary calcification despite intensive lipid-lowering treatment: A randomised controlled trial. Heart 92, 1207-1212 (2006
48. Hjortnaes, J. et al. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: A role for inflammation. Eur. Heart J. 31, 1975-1984 (2010
49. Dweck, M R. et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 125, 76-86 (2012
50. Dweck, M. R. et al. Coronary arterial 18F sodium fluoride uptake: A novel marker of plaque biology. J. Am. Coll. Cardiol. 59, 1539-1548 (2012
51. Giachelli, C. M. Vascular calcification mechanisms. J. Am. Soc. Nephrol. 15, 2959-2964 (2004
52. Goodman, W. G. et al. Vascular calcification in chronic kidney disease. Am. J. Kidney Dis. 43, 572-579 (2004
53. Aikawa, E et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 116, 2841-2850 (2007
54. Aikawa, E et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115, 377-386 (2007
55. Carter, S et al. Sirt1 inhibits resistin expression in aortic stenosis. PLoS ONE 7, e35110 (2012
56. Mohty, D. et al. Age-related differences in the pathogenesis of calcific aortic stenosis: The potential role of resistin. Int. J. Cardiol. 142, 126-132 (2010
57. New, S. E. et al. Macrophage-derived matrix vesicles: An alternative novel mechanism for microcalcification in atherosclerotic plaques. Circ. Res. 113, 72-77 (2013
58. Rajamannan, N M. et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107, 2181-2184 (2003
59. Wallin, R., Wajih, N., Greenwood, G. T. & Sane, D. C. Arterial calcification: A review of mechanisms, animal models, and the prospects for therapy. Med. Res. Rev. 21, 274-301 (2001
60. Neven, E., De Schutter, T M., De Broe, M. E. & D'Haese, P. C. Cell biological and physicochemical aspects of arterial calcification. Kidney Int. 79, 1166-1177 (2011
61. Li, X., Yang, H Y. & Giachelli, C. M. BMP 2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 199, 271-277 (2008
62. Dalfino, G et al. Bone morphogenetic protein 2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis 211, 418-423 (2010
63. Balderman, J. A. et al. Bone morphogenetic protein 2 decreases microRNA 30b and microRNA 30c to promote vascular smooth muscle cell calcification. J. Am. Heart Assoc. 1, e003905 (2012
64. Bertazzo, S. et al. Nano-Analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification. Nat. Mater. 12, 576-583 (2013
65. Kapustin, A. N. et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ. Res. 109, e1-e12 (2011
66. Ferdous, Z., Jo, H & Nerem, R. M. Differences in valvular and vascular cell responses to strain in osteogenic media. Biomaterials 32, 2885-2893 (2011
67. Yip, C. Y., Chen, J. H., Zhao, R. & Simmons, C. A. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler. Thromb. Vasc. Biol. 29, 936-942 (2009
68. O'Brien, K. D. et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler. Thromb. Vasc. Biol. 16, 523-532 (1996
69. Mohty, D. et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler. Thromb. Vasc. Biol. 28, 187-193 (2008
70. Mahmut, A. et al. Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling. Eur. J. Clin. Invest. 43, 570-578 (2013
71. Nadlonek, N. A., Lee, J. H., Weyant, M. J., Meng, X. & Fullerton, D. A. ox LDL induces PiT 1 expression in human aortic valve interstitial cells. J. Surg. Res. 184, 6-9 (2013
72. Pohle, K et al. Progression of aortic valve calcification: Association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104, 1927-1932 (2001
73. Aronow, W. S., Ahn, C., Kronzon, I. & Goldman, M. E. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am. J. Cardiol. 88, 693-695 (2001
74. Moura, L. M. et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J. Am. Coll. Cardiol. 49, 554-561 (2007
75. Novaro, G M. et al. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104, 2205-2209 (2001
76. Teo, K. K., Corsi, D. J., Tam, J. W., Dumesnil, J. G. & Chan, K. L. Lipid lowering on progression of mild to moderate aortic stenosis: Meta-Analysis of the randomized placebo-controlled clinical trials on 2344 patients. Can. J. Cardiol. 27, 800-808 (2011
77. Gould, A L., Rossouw, J. E., Santanello, N. C., Heyse, J. F. & Furberg, C. D. Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 97, 946-952 (1998
78. Ray, K. K. et al. Statins and all-cause mortality in high-risk primary prevention: A meta-Analysis of 11 randomized controlled trials involving 65,229 participants. Arch. Intern. Med. 170, 1024-1031 (2010
79. Libby, P. & Aikawa, M. Mechanisms of plaque stabilization with statins. Am. J. Cardiol. 91, 4B-8B (2003
80. Libby, P. & Aikawa, M. Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin. Cardiol. 26 (Suppl. 1), I11-I14 (2003
81. Benton, J. A., Kern, H. B., Leinwand, L. A., Mariner, P. D. & Anseth, K. S. Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression. Arterioscler. Thromb. Vasc. Biol. 29, 1950-1957 (2009
82. Bellamy, M. F., Pellikka, P. A., Klarich, K. W., Tajik, A. J. & Enriquez-Sarano, M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme A reductase inhibitor treatment, and progression of aortic stenosis in the community. J. Am. Coll. Cardiol. 40, 1723-1730 (2002
83. Cowell, S. J. et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352, 2389-2397 (2005
84. Rossebo, A. B. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359, 1343-1356 (2008
85. Gerdts, E. et al. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). Am. J. Cardiol. 106, 1634-1639 (2010
86. Chan, K L., Teo, K., Dumesnil, J. G., Ni, A. & Tam, J. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121, 306-314 (2010
87. Jassal, D. S. et al. Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. Cardiovasc. Ultrasound 9, 5 (2011
88. Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc. 2013.11.002
89. Monzack, E. L. & Masters, K. S. A time course investigation of the statin paradox among valvular interstitial cell phenotypes. Am. J. Physiol. Heart Circ. Physiol. 303, H903-H909 (2012
90. Capoulade, R. et al. Impact of metabolic syndrome on progression of aortic stenosis: Influence of age and statin therapy. J. Am. Coll. Cardiol. 60, 216-223 (2012
91. Thanassoulis, G. et al. Genetic associations with valvular calcification and aortic stenosis. N. Engl. J. Med. 368, 503-512 (2013
92. Jacobson, T. A. Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin. Proc. 88, 1294-1311 (2013
93. Chu, Y. et al. Pioglitazone attenuates valvular calcification induced by hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 33, 523-532 (2013
94. Yontar, O. C. & Yilmaz, M. B. Importance of serum high-density lipoprotein levels to aortic valvular disease. Br. J. Pharmacol. 155, 1163 (2008
95. Speidl, W. S. et al. Recombinant apolipoprotein A I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur. Heart J. 31, 2049-2057 (2010
96. Trapeaux, J. et al. Improvement of aortic valve stenosis by ApoA I mimetic therapy is associated with decreased aortic root and valve remodelling in mice. Br. J. Pharmacol. 169, 1587-1599 (2013
97. Lommi, J I. et al. High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification. Atherosclerosis 219, 538-544 (2011
98. Towler, D. A. Molecular and cellular aspects of calcific aortic valve disease. Circ. Res. 113, 198-208 (2013
99. Grinnell, F. & Ho, C. H. Transforming growth factor β stimulates fibroblast-collagen matrix contraction by different mechanisms in mechanically loaded and unloaded matrices. Exp. Cell Res. 273, 248-255 (2002
100. Merryman, W. D. et al. Synergistic effects of cyclic tension and transforming growth factor β1 on the aortic valve myofibroblast. Cardiovasc. Pathol. 16, 268-276 (2007
101. Walker, G. A., Masters, K. S., Shah, D. N., Anseth, K. S. & Leinwand, L. A. Valvular myofibroblast activation by transforming growth factor β: Implications for pathological extracellular matrix remodeling in heart valve disease. Circ. Res. 95, 253-260 (2004
102. Ghosh, J. et al. The role of transforming growth factor β1 in the vascular system. Cardiovasc. Pathol. 14, 28-36 (2005
103. Jian, B., Narula, N., Li, Q. Y., Mohler, E. R. 3rd & Levy, R. J. Progression of aortic valve stenosis: TGF β1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann. Thorac. Surg. 75, 457-465 (2003
104. Fisher, C. I., Chen, J. & Merryman, W. D. Calcific nodule morphogenesis by heart valve interstitial cells is strain dependent. Biomech. Model Mechanobiol. 12, 5-17 (2013
105. Chen, J. H., Chen, W. L., Sider, K. L., Yip, C. Y. & Simmons, C. A. β Catenin mediates mechanically regulated, transforming growth factor β1 induced myofibroblast differentiation of aortic valve interstitial cells. Arterioscler. Thromb. Vasc. Biol. 31, 590-597 (2011
106. Howe, P. H. in The Cytokine Handbook (eds Thomson, A. W. & Lotze, M. T.) 1119-1141 (Academic Press Inc., 2003
107. Zhang, Y E. Non-Smad pathways in TGF β signaling. Cell Res. 19, 128-139 (2009
108. Galliher, A J. & Schiemann, W. P. β3 Integrin and Src facilitate transforming growth factor β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 8, R42 (2006
109. Hutcheson, J. D., Ryzhova, L. M., Setola, V. & Merryman, W. D. 5 HT2B Antagonism arrests non-canonical TGF β1 induced valvular myofibroblast differentiation. J. Mol. Cell. Cardiol. 53, 707-714 (2012
110. Yanagawa, B. et al. miRNA 141 is a novel regulator of BMP 2 mediated calcification in aortic stenosis. J. Thorac. Cardiovasc. Surg. 144, 256-262 (2012
111. Kaden, J. J. et al. Expression of bone sialoprotein and bone morphogenetic protein 2 in calcific aortic stenosis. J. Heart Valve Dis. 13, 560-566 (2004
112. Yang, X. et al. Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: Role of Smad1 and extracellular signal-regulated kinase 1/2. J. Thorac. Cardiovasc. Surg. 138, 1008-1015 (2009
113. Balachandran, K., Sucosky, P., Jo, H. & Yoganathan, A. P. Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner. Am. J. Pathol. 177, 49-57 (2010
114. Kroeze, W. K., Sheffler, D. J. & Roth, B. L. G protein-coupled receptors at a glance. J. Cell Sci. 116, 4867-4869 (2003
115. Hutcheson, J. D., Setola, V., Roth, B. L. & Merryman, W. D. Serotonin receptors and heart valve disease-it was meant 2B. Pharmacol. Ther. 132, 146-157 (2011
116. Gustafsson, B. I., Hauso, O., Drozdov, I., Kidd, M. & Modlin, I. M. Carcinoid heart disease. Int. J. Cardiol. 129, 318-324 (2008
117. Connolly, H. M. et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581-588 (1997
118. Fitzgerald, L. W. et al. Possible role of valvular serotonin 5 HT2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57, 75-81 (2000
119. Rothman, R B. et al. Evidence for possible involvement of 5 HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841 (2000
120. Huang, X. P. et al. Parallel functional activity profiling reveals valvulopathogens are potent 5 hydroxytryptamine2B receptor agonists: Implications for drug safety assessment. Mol. Pharmacol. 76, 710-722 (2009
121. Setola, V. et al. 3,4 Methylenedioxymethamphetamine (MDMA, Ecstasy) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63, 1223-1229 (2003
122. Launay, J. M. et al. Function of the serotonin 5 hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 8, 1129-1135 (2002
123. Jaffré, F. et al. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ. Res. 104, 113-123 (2009
124. Helske, S. et al. Induction of local angiotensin II producing systems in stenotic aortic valves. J. Am. Coll. Cardiol. 44, 1859-1866 (2004
125. Brooke, B. S. et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N. Engl. J. Med. 358, 2787-2795 (2008
126. Cohn, R. D. et al. Angiotensin II type 1 receptor blockade attenuates TGF β induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13, 204-210 (2007
127. Habashi, J P. et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332, 361-365 (2011
128. Olsen, M. H. et al. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am. J. Cardiol. 94, 1076-1080 (2004
129. Côté, N., Couture, C., Pibarot, P., Després, J. P. & Mathieu, P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur. J. Clin. Inves. 41, 1172-1179 (2011
130. Nadir, M. A. et al. Impact of renin-Angiotensin system blockade therapy on outcome in aortic stenosis. J. Am. Coll. Cardiol. 58, 570-576 (2011
131. Capoulade, R. et al. Impact of hypertension and renin-Angiotensin system inhibitors in aortic stenosis. Eur. J. Clin. Inves. 43, 1262-1272 (2013
132. Arishiro, K. et al. Angiotensin receptor 1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J. Am. Coll. Cardiol. 49, 1482-1489 (2007
133. Judge, D. P., Rouf, R., Habashi, J. & Dietz, H. C. Mitral valve disease in Marfan syndrome and related disorders. J. Cardiovasc. Transl. Res. 4, 741-747 (2011
134. Chang, S. K. et al. Cadherin 11 regulates fibroblast inflammation. Proc. Natl Acad. Sci. USA 108, 8402-8407 (2011
135. Schneider, D J. et al. Cadherin 11 contributes to pulmonary fibrosis: Potential role in TGF β production and epithelial to mesenchymal transition. FASEB J. 26, 503-512 (2012
136. Lee, D M. et al. Cadherin 11 in synovial lining formation and pathology in arthritis. Science 315, 1006-1010 (2007
137. Okazaki, M. et al. Molecular cloning and characterization of OB cadherin, a new member of cadherin family expressed in osteoblasts. J. Biol. Chem. 269, 12092-12098 (1994
138. Hinz, B., Pittet, P., Smith-Clerc, J., Chaponnier, C. & Meister, J. J. Myofibroblast development is characterized by specific cell-cell adherens junctions. Mol. Biol. Cell 15, 4310-4320 (2004
139. Hutcheson, J. D. et al. Cadherin 11 regulates cell-cell tension necessary for calcific nodule formation by valvular myofibroblasts. Arterioscler. Thromb. Vasc. Biol. 33, 114-120 (2013
140. Garg, V et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437, 270-274 (2005
141. Niessen, K. & Karsan, A. Notch signaling in cardiac development. Circ. Res. 102, 1169-1181 (2008
142. Ladich, E., Nakano, M., Carter-Monroe, N & Virmani, R. Pathology of calcific aortic stenosis. Future Cardiol. 7, 629-642 (2011
143. Sun, L., Chandra, S & Sucosky, P. Ex vivo evidence for the contribution of hemodynamic shear stress abnormalities to the early pathogenesis of calcific bicuspid aortic valve disease. PLoS ONE 7, e48843 (2012
144. de la Pompa, J. L. & Epstein, J. A. Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev. Cell 22, 244-254 (2012
145. Andersson, E R., Sandberg, R. & Lendahl, U. Notch signaling: Simplicity in design, versatility in function. Development 138, 3593-3612 (2011
146. Tang, Y., Urs, S. & Liaw, L. Hairy-related transcription factors inhibit Notch-induced smooth muscle a actin expression by interfering with Notch intracellular domain/CBF 1 complex interaction with the CBF 1 binding site. Circ. Res. 102, 661-668 (2008
147. Sjolund, J et al. The notch and TGF β signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS ONE 6, e23057 (2011
148. Tang, Y. et al. Notch and transforming growth factor β (TGFβ) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. J. Biol. Chem. 285, 17556-17563 (2010
149. Masuda, S et al. Notch1 oncoprotein antagonizes TGF β /Smad-mediated cell growth suppression via sequestration of coactivator p300. Cancer Sci. 96, 274-282 (2005
150. Sun, Y et al. Notch4 intracellular domain binding to Smad3 and inhibition of the TGF β signaling. Oncogene 24, 5365-5374 (2005
151. Fu, Y. et al. Differential regulation of transforming growth factor β signaling pathways by Notch in human endothelial cells. J. Biol. Chem. 284, 19452-19462 (2009
152. Kennard, S., Liu, H. & Lilly, B. Transforming growth factor β (TGF β1) down-regulates Notch3 in fibroblasts to promote smooth muscle gene expression. J. Biol. Chem. 283, 1324-1333 (2008
153. Nigam, V. & Srivastava, D. Notch1 represses osteogenic pathways in aortic valve cells. J. Mol. Cell. Cardiol. 47, 828-834 (2009
154. Nus, M. et al. Diet-induced aortic valve disease in mice haploinsufficient for the Notch pathway effector RBPJK/CSL. Arterioscler. Thromb. Vasc. Biol. 31, 1580-1588 (2011
155. Yang, X. et al. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J. Am. Coll. Cardiol. 53, 491-500 (2009
156. Meng, X. et al. Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: Potential roles in aortic valve inflammation and stenosis. Am. J. Physiol. Cell Physiol. 294, C29-C35 (2008
157. Zeng, Q. et al. Notch1 promotes the pro-osteogenic response of human aortic valve interstitial cells via modulation of ERK1/2 and nuclear factor ?B activation. Arterioscler. Thromb. Vasc. Biol. 33, 1580-1590 (2013
158. Côté, N. et al. ATP acts as a survival signal and prevents the mineralization of aortic valve. J. Mol. Cell. Cardiol. 52, 1191-1202 (2012
159. Mahmut, A. et al. Elevated expression of Lp PLA2 in calcific aortic valve disease: Implication for valve mineralization. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.05.105
160. Osman, L., Chester, A H., Amrani, M., Yacoub, M. H. & Smolenski, R. T. A novel role of extracellular nucleotides in valve calcification: A potential target for atorvastatin. Circulation 114 (Suppl.), I566-I572 (2006
161. Aikawa, E et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 119, 1785-1794 (2009
162. Hinton, R. B. et al. Elastin haploinsufficiency results in progressive aortic valve malformation and latent valve disease in a mouse model. Circ. Res. 107, 549-557 (2010
163. Helske, S. et al. Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler. Thromb. Vasc. Biol. 26, 1791-1798 (2006
164. Balachandran, K., Sucosky, P., Jo, H. & Yoganathan, A. P. Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: Implications for degenerative aortic valve disease. Am. J. Physiol. Heart Circ. Physiol. 296, H756-H764 (2009
165. Aikawa, E & Otto, C. M. Look more closely at the valve: Imaging calcific aortic valve disease. Circulation 125, 9-11 (2012
166. Aikawa, E et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: Implications for postnatal adaptation, pathology, and tissue engineering. Circulation 113, 1344-1352 (2006